Mechanism of cardioprotective effect of erythropoietin-induced preconditioning in rat heart

Indian Journal of Pharmacology

Volumn 42, Issue 4, 2010, Pages 219-223

  Garg, Kavita ^a   Yadav, Harlokesh ^a   Singh, Manjeet ^a   Sharma, P L ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Epo preconditioning; ischemic preconditioning; JAK 2; PI 3K; PKC

Indexed keywords

CHELERYTHRINE; CREATINE KINASE MB; JANUS KINASE; LACTATE DEHYDROGENASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RECOMBINANT ERYTHROPOIETIN; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; DRUG EFFECT; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART PERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; NONHUMAN; PRACTICE GUIDELINE; RAT; SIGNAL TRANSDUCTION;

EID: 77956236542     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.68421     Document Type: Article

References (34)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136
2. Bolli R, Dawn B, Xun YT. Emerging role of the JAK/STAT pathway as a mechanism of protection against ischemia-reperfusion injury. J Mol Cell Cardiol 2001;33:1893-1896
3. Bolli R, Dawan B, Xuan YT. Role of the JAK/STAT pathway in protection against myocardial ischemia-reperfusion injury. Trends Cardiovasc Med 2003;13:72-79
4. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res 2002;90:377-379
5. Hassouna A, Matata BM, Galinanes M. PKC-ε is upstream and PKC-α is downstream of mito KATP channels in the signal transduction pathway of ischemic preconditioning of human myocardium. Am J Physiol Cell Physiol 2004;287:1418-1425
6. Moritz KM, Lim GB, Wintour EM. Developmental regulation of EPO and erythropoiesis. Am J Physiol Regul Integr Comp Physiol 1997;273:R1829-44.
7. Lipton AJ, Johnson MA, Macdonald T, Lieberman MW, Gozal D, Gaston B S Nitrosothiols signal the ventilatory response to hypoxia. Nature 2001;413:171-174
8. Vogt C, Pentz S, Rich IN. A role for the macrophage in normal hemopoiesis: III In vitro and in vivo EPO gene expression in macrophages detected by in situ hybridization. Exp Hematol 1989; 17:391-397
9. Shingo T, Sorokan ST, Shimazaki T, Weiss S. EPO regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-9743
10. Grasso G, Buemi M, Alafaci C. Benefcial effects of systemic administration of recombinant human EPO in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 2002;99:5627-5631
11. Kausz A, Watkins SL, Hansen C, Godwin DA, Palmer RB, Brandt JR ntraperitoneal EPO in children on peritoneal dialysis: A study of pharmacokinetics and effcacy. Am J Kidney Dis 1999;34:651-656
12. Brines ML, Ghezzi P, Keenan S, Agnello D, Lanerolle NC, Cerami C, et al. EPO crosses the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci\USA 2000;97:10526-10531
13. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: Role of EPO in vascular systems. J Hematother Stem Cell Res 2002;11:863-871
14. Baker JE. EPO mimics ischemic preconditioning. Vascul Pharmacol 2005;42:233-241
15. Rafee P, Shi Y, Su J, Pritchard KA, Jr Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005;100:187-197
16. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of EPO-mediated cardioprotection during ischemia-reperfusion injury: Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005;19:1323-1325
17. Fryer RM, Pratt PF, Hsu AK, Gross GJ. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced carardioprotection. J pharmacol Exp Ther 2001;296:642-649
18. Hattori R, Maulik N, Otani H, Zhu L, Cordis G. Engelman RM, et al. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 2001;33:1929-1936
19. Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, et al Mitochondrial PKCε and MAPK form signaling modules in the murine heart: Enhanced mitochondrial PKCε-MAPK interactions and differential MAPK activation in PKC-induced cardioprotection. Circ Res 2002;90:390-397
20. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;61:427-436
21. Shi Y, Rafee P, Su J, Pritchard Jr KA, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 2004;99:173-182
22. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning Cardiovasc Res 2004;63:611-616
23. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opoid-nduced cardioprotection: JAK2 as a mediator of STAT3, AKT, and GSK-3beta Am J Physiol Heart Circ Physiol 2006;291:H827-34
24. Downey JM, Davis AM, Cohen MV. Signalling pathways in ischemic preconditioning. Heart Fail Rev 2007;12:181-188
25. Gross ER, Gross GJ. Ischemic preconditioning and myocardial infarction An update and perspective. Drug Discovery Today: Disease Mechanisms 2007;4:159-163
26. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, et al. EPO affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3β. Am J Physiol Heart Circ Physiol 2006;291:748-755
27. Langendorff O. Untersuchungen an uberlebenden Saugethierherzen. Pfugers Arch 1895;61:291-332.
28. Chopra K, Singh M, Kaul N, Andrabi KI, Ganguly NK. Decrease Decrease of myocardial infarct size with desferrioxamine: Possible role of oxygen free radicals in its ameliorative effect. Mol Cell Biochem 1992;13:71-76
29. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031-1033
30. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protect the myocardium against ischemia-reperfusion induced injury in vitro and in vivo. Basic Res Cardiol 2005;100:397-403.
31. Van Der Meer P, Lipsic E, Henning RH, Boddeus K, Van Der velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rat with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133
32. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, et al. GSK-3 beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004;113:1535-1549
33. Chan CY, Chen YS, Lec H H, Huang HS, Lai YL, Chen CF, et al. EPO protects post-ischemic hearts by preventing extracellular matrix degradation: Role of JAK2-ERK pathway. Life Sci 2007;81:717-723
34. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for EPO-mediated acute protection against myocardial ischemia-reperfusion injury. Circulation 2004;109:2050-2053